February 2020

Optogenerapy > 2020

The European Optogenerapy project has developed the first subcutaneous biophotonic implant using optogenetic technology to deliver doses of therapeutic proteins to patients with Multiple Sclerosis. The device has been pre-clinically validated and features a printed circuit board that activates a light source which controls therapeutic Interferon Beta (IFN-ß) protein production by genetically engineered cells confined within the implant. Biotza Gutiérrez, the consortium’s coordinator from Eurecat...

Read More
Optogenerapy final meeting

Eurecat has hosted the 37-month meeting of Optogenerapy project in its facilities in Cerdanyola del Valles. On January 23-24, partners reviewed the work done during the project and prepared themselves for the review meeting taking place in March. On January 24, a final public event to present the project results took place, gathering almost 60 persons interested in the project. ...

Read More
Optogenerapy